[Pharmacokinetics of habekacin in patients with chronic renal insufficiency].
Pharmacokinetics of habekacin, a new semisynthetic aminoglycoside antibiotic were investigated in six healthy subjects and twenty-five uraemic patients (six of whom were on hemodialysis) after a single 3 mg/kg Im or IV administration. After the IM injection, the peak serum levels were higher and the times to peak levels were longer in patients with renal impairment than in healthy subjects. Elimination serum half-life increased in relation to the degree of renal impairment, from 2 h in normal subjects to 32 h in patients with creatinine clearance below 10 ml/min. Renal impairment did not significantly modify the apparent volume of distribution. After a single 3 mg/kg dose as one hour-IV infusion in six hemodialysis patients, elimination half-life averaged 48 h and 5 h, out of and on a 4 to 5 hour-hemodialysis session, respectively. Habekacin pharmacokinetic parameters appeared to be similar to those of the other available aminoglycoside antibiotics.
Fillastre
J P
JP
Service de Néphrologie, Hôpital de Bois-Guillaume.
Leroy
A
A
Humbert
G
G
Moulin
B
B
Bernadet
P
P
Josse
S
S
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000031:analogs & derivatives*; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D006435:Renal Dialysis
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; D007612:Kanamycin; C031986:arbekacin
Pharmacocinétique de l'habékacine chez les malades atteints d'insuffisance rénale chronique.